Belantamab Mafodotin
drug drugOn this page
Also known as Belantamab mafodotin blmfBelantamab mafodotin-blmfBelantamab mafodotinaBelantamab mafodotineBlenrepGSK-2857916GSK2857916
Summary
Belantamab Mafodotin (CHEMBL4298209) is an approved antibody drug conjugate (ATC L01FX15) targeting TNFRSF17; indicated across 5 conditions including plasma cell myeloma and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody drug conjugate
- ATC class: L01FX15
- Targets: 1 (TNFRSF17)
- Indications: 5 conditions
- Clinical trials: 67
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298209 |
| Name | Belantamab Mafodotin |
| Type | Antibody drug conjugate |
| Max phase | 4 |
| ATC | L01FX15 |
Also known as: Belantamab mafodotin, Belantamab mafodotin blmf, Belantamab mafodotin-blmf, Belantamab mafodotina, Belantamab mafodotine, Blenrep, GSK-2857916, GSK2857916, BELANTAMAB MAFODOTIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| TNFRSF17 | B cell maturation antigen | Binding | 9.82 | 0.1% | Q02223 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): TNFRSF17.
Top Reactome pathways
1 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| TNFs bind their physiological receptors | 1 | TNFRSF17 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| adaptive immune response | 1 |
| lymphocyte homeostasis | 1 |
| signal transduction | 1 |
| tumor necrosis factor-mediated signaling pathway | 1 |
| immune system process | 1 |
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| plasma cell myeloma | 4 | MONDO:0009693 | EFO:0001378 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| diffuse large B-cell lymphoma | 2 | MONDO:0018905 | EFO:0000403 |
| hereditary amyloidosis | 2 | MONDO:0018634 | MONDO:0019438 |
| amyloidosis | 1 | MONDO:0019065 | EFO:1001875 |
Clinical trials
Total trials: 67.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 25 |
| PHASE2 | 17 |
| PHASE1 | 11 |
| PHASE3 | 9 |
| Not specified | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04162210 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT04246047 | PHASE3 | ACTIVE_NOT_RECRUITING | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT04484623 | PHASE3 | ACTIVE_NOT_RECRUITING | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma |
| NCT06679101 | PHASE3 | RECRUITING | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) |
| NCT06868654 | PHASE3 | ACTIVE_NOT_RECRUITING | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT06868667 | PHASE3 | ACTIVE_NOT_RECRUITING | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT06956170 | PHASE3 | ACTIVE_NOT_RECRUITING | All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma |
| NCT04549363 | PHASE3 | TERMINATED | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin |
| NCT05461209 | PHASE3 | WITHDRAWN | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT02343042 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Selinexor and Backbone Treatments of Multiple Myeloma Patients |
| NCT04126200 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT04643002 | PHASE1/PHASE2 | RECRUITING | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol |
| NCT04680468 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma |
| NCT04802356 | PHASE2 | ACTIVE_NOT_RECRUITING | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients |
| NCT04808037 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma |
| NCT04822337 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma |
| NCT04876248 | PHASE2 | ACTIVE_NOT_RECRUITING | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant |
| NCT05002816 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma |
| NCT05060627 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide |
| NCT05091372 | PHASE2 | RECRUITING | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma |
| NCT05145816 | PHASE1/PHASE2 | RECRUITING | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis |
| NCT05208307 | PHASE2 | RECRUITING | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma |
| NCT05573802 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma |
| NCT05581875 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory |
| NCT05714839 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments |
| NCT05789303 | PHASE2 | RECRUITING | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma |
| NCT05847569 | PHASE2 | RECRUITING | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma |
| NCT05853965 | PHASE1/PHASE2 | RECRUITING | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma |
| NCT05874193 | PHASE2 | NOT_YET_RECRUITING | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma |
| NCT05922501 | PHASE2 | RECRUITING | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma |
| NCT06232044 | PHASE1/PHASE2 | RECRUITING | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT07019545 | PHASE2 | NOT_YET_RECRUITING | A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY |
| NCT07084896 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM |
| NCT07150091 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM |
| NCT07150104 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM |
| NCT07217119 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM |
| NCT07217184 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM |
| NCT07224672 | PHASE2 | NOT_YET_RECRUITING | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis |
| NCT07227311 | PHASE2 | RECRUITING | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) |
| NCT07614360 | PHASE2 | NOT_YET_RECRUITING | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma |
| NCT03544281 | PHASE1/PHASE2 | COMPLETED | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT03732703 | PHASE1/PHASE2 | COMPLETED | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
| NCT03848845 | PHASE1/PHASE2 | COMPLETED | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT04617925 | PHASE2 | COMPLETED | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis |
| NCT04676360 | PHASE2 | TERMINATED | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma |
| NCT05064358 | PHASE2 | COMPLETED | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05117008 | PHASE2 | TERMINATED | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma |
| NCT05280275 | PHASE1/PHASE2 | UNKNOWN | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible |
| NCT05493618 | PHASE1/PHASE2 | WITHDRAWN | Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. |
| NCT06160609 | PHASE1/PHASE2 | TERMINATED | Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM |
| NCT06655818 | PHASE1/PHASE2 | TERMINATED | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM |
| NCT04091126 | PHASE1 | ACTIVE_NOT_RECRUITING | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma |
| NCT04398745 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function |
| NCT05055063 | PHASE1 | RECRUITING | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma |
| NCT05556798 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment |
| NCT07609706 | PHASE1 | NOT_YET_RECRUITING | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment |
| NCT02064387 | PHASE1 | COMPLETED | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 |
| NCT03828292 | PHASE1 | COMPLETED | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments |
| NCT04177823 | PHASE1 | COMPLETED | A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT04398680 | PHASE1 | WITHDRAWN | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function |
| NCT04892264 | PHASE1 | TERMINATED | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma |
| NCT05065047 | PHASE1 | TERMINATED | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma |
| NCT03763370 | Not specified | AVAILABLE | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma |
| NCT05297240 | Not specified | UNKNOWN | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. |
| NCT05393024 | Not specified | COMPLETED | Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy |
| NCT05833737 | Not specified | TERMINATED | Corneal Findings in Patients Treated With Belantamab Mafodotin |
| NCT05986682 | Not specified | COMPLETED | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: TNFRSF17
- Indicated for: plasma cell myeloma, neoplasm
- In clinical trials for: diffuse large B-cell lymphoma, hereditary amyloidosis